Abstract Number: 2534 • ACR Convergence 2025
Frequency of Ocular and Gastrointestinal Lesions Is Increased in Japanese Behçet’s Disease Patients with HLA-B61
Background/Purpose: The associations of HLA-B51 and HLA-A26 with the onset of Behçet’s disease (BD) are well established. Although BD manifests with a variety of clinical…Abstract Number: 2535 • ACR Convergence 2025
Behçet’s syndrome: distinct features in 344 pediatric and adult patients in a non-endemic region
Background/Purpose: Behçet’s syndrome (BS) is a chronic inflammatory disorder characterized by a heterogeneous clinical presentation, occurring primarily in young adults and very rarely in children…Abstract Number: 2527 • ACR Convergence 2025
Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial
Background/Purpose: Although rare, new-onset Behçet’s syndrome (BS) and disease flares have been reported following vaccination. In this context, the recommendation of the Recombinant Herpes Zoster…Abstract Number: 2045 • ACR Convergence 2025
Malignancy in Behçet’s Syndrome: A 24-Year Cohort Study In a Non-Endemicand Multiethnic Country
Background/Purpose: Behçet’s syndrome (BS) has been associated with an increased risk of malignancy, particularly in studies from endemic regions such as East Asia and the…Abstract Number: 2037 • ACR Convergence 2025
The Largest International Cohort Study of HA20 Reveals Novel Genetic Architecture and Age-Dependent Phenotypic Evolution
Background/Purpose: Haploinsufficiency of A20 (HA20) is a monogenic autoinflammatory disease caused by loss-of-function (LOF) mutations in TNFAIP3. HA20 was initially described as an early-onset form…Abstract Number: 2028 • ACR Convergence 2025
Behçet’s Syndrome Beyond Endemic Borders: A 24-Year Longitudinal Analysis of Mortality in a Diverse South American Cohort
Background/Purpose: Behçet’s syndrome (BS) is a chronic, relapsing vasculitis that contributes substantially to morbidity and mortality, primarily due to vascular and neurological complications. Most of…Abstract Number: 1292 • ACR Convergence 2025
Childhood-onset Behçet’s disease: HLA alleles role on diagnosis and treatment in a Latin American tertiary center
Background/Purpose: Behçet’s disease (BD) is a rare pediatric vasculitis with limited epidemiological data in Latin America centers, especially in children where initial symptoms can be…Abstract Number: 1180 • ACR Convergence 2025
Gender-Based Clinical Differences in Behçet’s Syndrome: Findings from a 24-Year Cohort in a Non-Endemic and Multiethnic Country
Background/Purpose: Behçet’s syndrome (BS) is a multisystemic inflammatory condition that affects both genders, although gender-related differences in disease manifestations may vary across regions. Studies report…Abstract Number: 1098 • ACR Convergence 2025
Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Background/Purpose: Apremilast, a PDE-4 inhibitor, is commonly indicated for patients with psoriasis as well as Behçet’s disease. Although this medication is generally well tolerated, numerous…Abstract Number: 1074 • ACR Convergence 2025
Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis
Background/Purpose: Racial/ethnic disparities in Behçet’s disease (BD) outcomes are largely undocumented in the United States. Given known differences in disease expression across populations globally, we…Abstract Number: 2544 • ACR Convergence 2025
Diagnostic value of vein wall thickness measurement for patients with suspected Behçet syndrome
Background/Purpose: Several studies have demonstrated increased venous wall thickness (VWT) in patients with Behçet’s syndrome (BS) compared to healthy and diseased control groups. Ultrasonographic measurement…Abstract Number: 0275 • ACR Convergence 2025
A snapshot of subcutaneous infliximab use in inflammatory rheumatic diseases: a multicenter Italian study
Background/Purpose: A new subcutaneous formulation of infliximab (CT-P13) has recently become available for the treatment of inflammatory rheumatic diseases (IRDs), psoriasis and inflammatory bowel diseases.…Abstract Number: 2543 • ACR Convergence 2025
Severe Visual Impairment in Behçet Syndrome in Time: A Comparison of Four Time Periods
Background/Purpose: There is consensus that the visual prognosis in Behçet syndrome (BS) uveitis has considerably improved in time (1-3). We wanted to better quantitate this…Abstract Number: 0272 • ACR Convergence 2025
Ocular Involvement in Behçet’s Disease: Comparative Study of Two Classification Criteria in Clinical Practice
Background/Purpose: Ocular involvement is a potential severe complication of Behçet’s Disease (BD). The traditional classification, by the International Study Group (ISG, 1990) requires the mandatory…Abstract Number: 2541 • ACR Convergence 2025
Development of Severity Classification Criteria for Introduction of Infliximab for Chronic Pogressive Neuro-Behçet’s Disease
Background/Purpose: Chronic progressive neuro-Behçet’s disease (CPNB) is characterized by progressive deterioration leading to disability and death. It has been appreciated that methotrexate (MTX) has beneficial…
- 1
- 2
- 3
- …
- 6
- Next Page »